The levels of TNF-α in the model group were initially 1013.51 ± 7.49 ng/L, 945.65 ± 5.99 ng/L, 890.07 ± 8.30 ng/L, and 992.28 ± 4.90 ng/L, respectively, but significantly decreased after treatment with quadrigemine I, with inhibition rates of 10.28 ± 0.64% and 49.83 ± 0.39% in serum, 2.49 ± 1.11% and 34.59 ± 1.11% in liver tissue, 2.22 ± 0.30% and 27.90 ± 0.09% in spleen tissue, and 3.79 ± 0.87% and 24.48 ± 1.05% in tumor tissue. The gene discussed is TNF; the disease is neoplasm.